KEYNOTE-158 is a larger phase II basket trial using pembrolizumab in 11 cancer types including advanced recurrent SCLC, nevertheless, unlike Keynote-028, regardless of PD-L1 status. This evidence concerns the gene CD274 and small cell lung carcinoma.